Tîroid Fonksiyon Testleri ile C-Reaktif Protein Düzeyleri Arasındaki İlişki

Yıl 2007, Cilt: 1 Sayı: 1, 34 - 37, 20.03.2007

Dilek Tüzün

Öz

C-reaktif protein (CRP), son zamanlarda önemi ortaya çıkan kardiyovasküler risk belirteçlerinden biri olmasına rağmen tiroid fonksiyon testlerine göre CRP düzeyindeki değişimler, çalışmalara göre farklılık göstermektedir. Bu nedenle çalışmamızda tiroid fonksi-yon testleri ile CRP arasında ilişki olup olmadığını araştırdık.
Çalışmaya 75 olgu dahil edildi. Vakaların eşlik eden sistemik ya da inflamatuar hastalıkları mevcut değildi. Çalışmaya dahil edilen olgulann; tiroid fonksiyon testleri ve yüksek sensitif CRP (hs-CRP) düzeyleri ölçüldü.
Olgulann 57 (%76)’si kadın, 18 (%24)’i erkekti. Yaş ortalama¬ları 48.89 ± 14.57 yıl idi. Bunlardan 33 (%44)’ü ötiroid, 17 (%23)’si subklinik hipotiroid, 13 (%17)’ü subklinik hipertiroid, 12(%16)’si de klinik hipertiroid idi. Grubun ortalama hs-CRP düzeyleri 2.94 ± 2.57 mg/L idi. Gruplar arasında hs-CRP düzeyleri açısından istatistiksel anlamlı fark saptanmadı.
Çalışmamız sonucunda ateroskleroz açısından risk faktörü olan hs-CRP düzeylerinin tiroid fonksiyon testlerine göre değişiklik gös¬termediğini saptadık .

Abstract
Recently, serum C-reactive protein (CRP) have emerged as a new cardiovascular risk factor, but studies on changes of these markers with respect to thyroid function status have produced variable results. We investigated the relation between CRP and tyhroid status in cases with differing severities of thyroid dysfunction.
Seventy five patients were enrolled in the study. Patients didn’t have any systemic or inflamatory disease. Thyroid function tests and high sensitive CRP(hs-CRP) levels were measured.
Fifty seven (76%) of cases were women and 18 (24%) of men. The mean age was 48.89 ± 14.57. Thirthy three patients (44%) with euthyroidism, 17 (23%) patients with subclinical hypothyroidism, 13 (17%) patients with subclinical hyperthyroidism, 12 (16%) patients with hyperthyroidism were evaluated. Mean hs-CRP levels were 2.94 ± 2.57 mg/L. There were no significant difference in hs-CRP levels between groups.
We found no difference in hs-CRP levels, a risk factor for atherosclerosis, according to tyhroid function status according to our study.

Anahtar Kelimeler

Tiroid fonksiyon testleri, CRP, tiroid,

Kaynakça

• 1. WagnerH,WagnerM. Conus type hip-prosthesis. Acta Chir Orthop Traumatol Cech 2001;68:213-21.
• 2. Weber M. HempfingA, OrlerR,Ganz; Femoral revision using the Wagner stem: Results at 2-9 years. R Int Orthop 2002;26:36-9.
• 3. Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 1973;55:1629-32.
• 4. Kolstad K. Revision THR after periprosthetic femoral fractures. An analysis of 23 cases. Acta Orthop Scand 1994;65:505-8.
• 5. Kolstad K, Adalbreth G, Malimin H, Milbrink J, Sahlsttedt B. The Wagner Revision Stem for Severe Osteolysis. Acta Orthop Scan 1996;67:541-4.
• 6. Ko PS, Lam JJ, Tio MK, Lee OB, Ip FK. Distal fixation with Wagner revision stem in treating Vancouver type B2 peri prosthetic femur fractures in geriatric patients. J Arthroplasty 2003;18:446-5.
• 7. Böhm P, Bischel O, Femoral Revision with the Wagner SL Revision Stem. Evaluation of One Hundred and Twenty-nine Revisions Followed for a Mean of 4.8 Years. The Journal of Bone and Joint Surgery 2001 ;83:1023-31.
• 8. BohmP, BischelO, The use of tapered stems for femoral revision hip surgery. Clin Orthop 2004;420:148-59.
• 9. IsacsonJ, StarkA, Wallensten R The Wagner revision prosthesis consistently restores femoral bone structure. Int Orthop. 2000;24:139-42.
• 10. Grunig R, Morsher E, Ochsner PE. Three-to 7-year Results with the Uncemcntcd SL Femoral Revision Prothesis. Arch Orthop Trauama Surg 1997; 116:187-97.